HRP20231314T1 - Stopljeni pirimidinski spojevi kao modulatori kcc2 - Google Patents
Stopljeni pirimidinski spojevi kao modulatori kcc2 Download PDFInfo
- Publication number
- HRP20231314T1 HRP20231314T1 HRP20231314TT HRP20231314T HRP20231314T1 HR P20231314 T1 HRP20231314 T1 HR P20231314T1 HR P20231314T T HRP20231314T T HR P20231314TT HR P20231314 T HRP20231314 T HR P20231314T HR P20231314 T1 HRP20231314 T1 HR P20231314T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- dihydro
- propan
- pyrrolo
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989104P | 2020-03-13 | 2020-03-13 | |
| EP21712145.8A EP4103566B1 (en) | 2020-03-13 | 2021-03-12 | Fused pyrimidine compounds as kcc2 modulators |
| PCT/EP2021/056393 WO2021180952A1 (en) | 2020-03-13 | 2021-03-12 | Fused pyrimidine compounds as kcc2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231314T1 true HRP20231314T1 (hr) | 2024-02-16 |
Family
ID=74874882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231314TT HRP20231314T1 (hr) | 2020-03-13 | 2021-03-12 | Stopljeni pirimidinski spojevi kao modulatori kcc2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12617795B2 (enExample) |
| EP (1) | EP4103566B1 (enExample) |
| JP (2) | JP7793529B2 (enExample) |
| KR (1) | KR20220152319A (enExample) |
| CN (4) | CN119684300A (enExample) |
| AU (1) | AU2021234134B2 (enExample) |
| BR (1) | BR112022018173A2 (enExample) |
| CA (1) | CA3171192A1 (enExample) |
| CL (1) | CL2022002386A1 (enExample) |
| CO (1) | CO2022012884A2 (enExample) |
| DK (1) | DK4103566T3 (enExample) |
| ES (1) | ES2962136T3 (enExample) |
| FI (1) | FI4103566T3 (enExample) |
| HR (1) | HRP20231314T1 (enExample) |
| HU (1) | HUE064037T2 (enExample) |
| IL (1) | IL296265B2 (enExample) |
| LT (1) | LT4103566T (enExample) |
| MX (1) | MX2022011354A (enExample) |
| PE (1) | PE20230106A1 (enExample) |
| PL (1) | PL4103566T3 (enExample) |
| PT (1) | PT4103566T (enExample) |
| RS (1) | RS64823B1 (enExample) |
| SI (1) | SI4103566T1 (enExample) |
| SM (1) | SMT202300384T1 (enExample) |
| WO (1) | WO2021180952A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022407047A1 (en) * | 2021-12-08 | 2024-07-25 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
| CN121548571A (zh) * | 2023-04-05 | 2026-02-17 | 艾索尼斯治疗公司 | Kcc2增强剂及其用途 |
| US20250281497A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of seizure disorders |
| WO2025188977A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of addiction and insomnia |
| WO2025188974A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics |
| WO2025188973A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes |
| US20260048062A1 (en) * | 2024-03-06 | 2026-02-19 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders |
| WO2025188952A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies |
| WO2025188953A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain |
| US20250281500A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease |
| US20260048063A1 (en) * | 2024-03-06 | 2026-02-19 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neurodegenerative disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| HRP20140395T1 (hr) | 2008-08-20 | 2014-06-06 | Zoetis Llc | SPOJEVI PIROLO[2,3-d]PIRIMIDINA |
| EP4019518A1 (en) | 2014-02-28 | 2022-06-29 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| US11331313B2 (en) | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
| WO2019045824A1 (en) | 2017-09-01 | 2019-03-07 | Kadmon Corporation, Llc | ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO |
| WO2019226643A1 (en) | 2018-05-25 | 2019-11-28 | The Children's Medical Center Corporation | Methods for treating spinal cord injury |
-
2021
- 2021-03-12 WO PCT/EP2021/056393 patent/WO2021180952A1/en not_active Ceased
- 2021-03-12 ES ES21712145T patent/ES2962136T3/es active Active
- 2021-03-12 PL PL21712145.8T patent/PL4103566T3/pl unknown
- 2021-03-12 PT PT217121458T patent/PT4103566T/pt unknown
- 2021-03-12 EP EP21712145.8A patent/EP4103566B1/en active Active
- 2021-03-12 CA CA3171192A patent/CA3171192A1/en active Pending
- 2021-03-12 FI FIEP21712145.8T patent/FI4103566T3/fi active
- 2021-03-12 SM SM20230384T patent/SMT202300384T1/it unknown
- 2021-03-12 PE PE2022001943A patent/PE20230106A1/es unknown
- 2021-03-12 CN CN202411881526.5A patent/CN119684300A/zh active Pending
- 2021-03-12 IL IL296265A patent/IL296265B2/en unknown
- 2021-03-12 JP JP2022554784A patent/JP7793529B2/ja active Active
- 2021-03-12 KR KR1020227035465A patent/KR20220152319A/ko not_active Ceased
- 2021-03-12 CN CN202411881248.3A patent/CN119684299A/zh active Pending
- 2021-03-12 SI SI202130073T patent/SI4103566T1/sl unknown
- 2021-03-12 MX MX2022011354A patent/MX2022011354A/es unknown
- 2021-03-12 US US17/911,051 patent/US12617795B2/en active Active
- 2021-03-12 LT LTEPPCT/EP2021/056393T patent/LT4103566T/lt unknown
- 2021-03-12 DK DK21712145.8T patent/DK4103566T3/da active
- 2021-03-12 CN CN202411881483.0A patent/CN119735594A/zh active Pending
- 2021-03-12 RS RS20231022A patent/RS64823B1/sr unknown
- 2021-03-12 HR HRP20231314TT patent/HRP20231314T1/hr unknown
- 2021-03-12 HU HUE21712145A patent/HUE064037T2/hu unknown
- 2021-03-12 BR BR112022018173A patent/BR112022018173A2/pt unknown
- 2021-03-12 AU AU2021234134A patent/AU2021234134B2/en active Active
- 2021-03-12 CN CN202180020856.3A patent/CN115298182B/zh active Active
-
2022
- 2022-09-01 CL CL2022002386A patent/CL2022002386A1/es unknown
- 2022-09-09 CO CONC2022/0012884A patent/CO2022012884A2/es unknown
-
2025
- 2025-09-12 JP JP2025151939A patent/JP2025186368A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517680A5 (enExample) | ||
| JP2025186368A5 (enExample) | ||
| KR101917972B1 (ko) | ERK 억제제로서 티에노[2,3-c]피롤-4-온 유도체 | |
| AU2022328206A1 (en) | Heterocyclic compounds and methods of use | |
| KR101507182B1 (ko) | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 | |
| RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
| HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
| HRP20231614T1 (hr) | Spojevi pirolotriazina kao tam inhibitori | |
| JP2010512337A5 (enExample) | ||
| JP2022552324A5 (enExample) | ||
| HRP20240994T1 (hr) | Spoj inhibitora jak i njegova uporaba | |
| JP2022542396A5 (enExample) | ||
| CA2528848C (en) | Thienopyrimidine derivatives as potassium channel inhibitors | |
| JP2009519979A5 (enExample) | ||
| RU2009125897A (ru) | Ингибиторы фосфоинозитид-3-киназы и способы их применения | |
| HRP20220144T1 (hr) | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora | |
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| WO2022093856A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2018529731A5 (enExample) | ||
| ME01507B (me) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| RU2006102955A (ru) | Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов | |
| CN107108614A (zh) | 作为布罗莫结构域抑制剂的取代的吡咯并吡啶 | |
| JP2010512338A5 (enExample) | ||
| US20140088076A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| ME02635B (me) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže |